DÄ internationalArchive45/2006Autoimmune Thyroid Disease

Review article

Autoimmune Thyroid Disease

Dtsch Arztebl 2006; 103(45): A-3023

Schott, M; Scherbaum, W A

For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.

1. Laurberg P, Pedersen KM, Hreidarsson A, Sigfusson N, Iversen E, Knudsen PR: Iodine intake and the pattern of thyroid disorders: a comparative epidemiological study of thyroid abnormalities in the elderly in Iceland and in Jutland, Denmark. J Clin Endocrinol Metab 1998; 83: 765–9. MEDLINE
2. Quaratino S, Badami E, Pang YY, Bartok I, Dyson J, Kioussis D et al.: Degenerate self-reactive human T-cell receptor causes spontaneous autoimmune disease in mice. Nat Med 2004; 10: 920–6. MEDLINE
3. Heuer M, Aust G, Ode-Hakim S, Scherbaum WA: Different cytokine mRNA profiles in Graves' disease, Hashimoto's thyroiditis, and nonautoimmune thyroid disorders determined by quantitative reverse transcriptase polymerase chain reaction (RT-PCR). Thyroid 1996; 6: 97–106. MEDLINE
4. Imaizumi M, Pritsker A, Unger P, Davies TF: Intrathyroidal fetal microchimerism in pregnancy and postpartum. Endocrinology 2002; 143: 247–53. MEDLINE
5. Mariotti S, Sansoni P, Barbesino G et al.: Thyroid and other organ-specific autoantibodies in healthy centenarians. Lancet 1992; 339: 1506–8. MEDLINE
6. Vanderpump MP, Tunbridge WM, French JM et al.: The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin Endocrinol (Oxf) 1995; 43: 55–68. MEDLINE
7. Hollowell JG, Staehling NW, Flanders WD et al.: Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2002; 87: 489–99. MEDLINE
8. Surks MI, Ortiz E, Daniels GH et al.: Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA 2004; 291: 228–38. MEDLINE
9. Brix TH, Kyvik KO, Christensen K, Hegedus L: Evidence for a major role of heredity in Graves' disease: a population-based study of two Danish twin cohorts. J Clin Endocrinol Metab 2001; 86: 930–4. MEDLINE
10. Holm IA, Manson JE, Michels KB, Alexander EK, Willett WC, Utiger RD: Smoking and other lifestyle factors and the risk of Graves' hyperthyroidism. Arch Intern Med 2005; 165: 1606–11. MEDLINE
11. Ando T, Latif R, Pritsker A, Moran T, Nagayama Y, Davies T: A monoclonal thyroid-stimulating antibody. J Clin Invest 2002; 110: 1667–74. MEDLINE
12. Costagliola S, Franssen JD, Bonomi M et al.: Generation of a mouse monoclonal TSH receptor antibody with stimulating activity. Biochem Biophys Res Commun 2002; 299: 891–6. MEDLINE
13. Sanders J, Evans M, Premawardhana LD et al.: Human monoclonal thyroid stimulating autoantibody. Lancet 2003; 362: 126–8. MEDLINE
14. Bahn RS, Dutton CM, Natt N, Joba W, Spitzweg C, Heufelder AE: Thyrotropin receptor expression in Graves' orbital adipose/connective tissues: potential autoantigen in Graves' ophthalmopathy. J Clin Endocrinol Metab 1998; 83: 998–1002. MEDLINE
15. Costagliola S, Morgenthaler NG, Hoermann R et al.: Second generation assay for thyrotropin receptor antibodies has superior diagnostic sensitivity for Graves' disease. J Clin Endocrinol Metab 1999; 84: 90–7. MEDLINE
16. Morgenthaler NG: New assay systems for thyrotropin receptor antibodies. Curr Opin Endocrinol Diabetes 1999; 6: 251–60.
17. Maugendre D, Massart C: Clinical value of a new TSH binding inihibitory activity assay using human TSH receptors in the follow-up of antithyroid drug treated Graves' disease. Comparison with thyroid stimulating antibody bioassay. Clin Endocrinol (Oxf) 2001; 54: 89–96. MEDLINE
18. Massart C, Orgiazzi J, Maugendre D: Clinical validity of a new commercial method for detection of TSH-receptor binding antibodies in sera from patients with Graves' disease treated with antithyroid drugs. Clin Chim Acta 2001; 304: 39–47. MEDLINE
19. Schott M, Feldkamp J, Bathan C, Fritzen R, Scherbaum WA, Seissler J: Detecting TSH-receptor antibodies with the recombinant TBII assay: technical and clinical evaluation. Horm Metab Res 2000; 32: 429–35. MEDLINE
20. Schott M, Morgenthaler NG, Fritzen R et al.: Levels of autoantibodies against human TSH receptor predict relapse of hyper-thyroidism in Graves' disease. Horm Metab Res 2004; 36: 92–6. MEDLINE
21. Quadbeck B, Hoermann R, Roggenbuck U, Hahn S, Mann K, Janssen OE: Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves' disease. Thyroid 2005; 15: 1047–54. MEDLINE
22. Eckstein AK, Plicht M, Lax H et al.: Clinical results of anti-inflammatory therapy in Graves' ophthalmopathy and association with thyroidal autoantibodies. Clin Endocrinol (Oxf) 2004; 61: 612–8. MEDLINE
23. Morgenthaler NG, Pampel I, Aust G, Seissler J, Scherbaum WA: Application of a bioassay with CHO cells for the routine detection of stimulating and blocking autoantibodies to the TSH-receptor. Horm Metab Res 1998; 30: 162–8. MEDLINE
24. Schott M, Minich WB, Willenberg HS et al.: Relevance of TSH receptor stimulating and blocking autoantibody measurement for the prediction of relapse in Graves' disease. Horm Metab Res 2005; 37: 741–4. MEDLINE
25. Quadbeck B, Hoermann R, Hahn S, Roggenbuck U, Mann K, Janssen OE: Binding, stimulating and blocking TSH receptor antibodies to the thyrotropin receptor as predictors of relapse of Graves' disease after withdrawal of antithyroid treatment. Horm Metab Res 2005; 37: 745–50. MEDLINE